ES2389670T8 - Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional - Google Patents
Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional Download PDFInfo
- Publication number
- ES2389670T8 ES2389670T8 ES08785844T ES08785844T ES2389670T8 ES 2389670 T8 ES2389670 T8 ES 2389670T8 ES 08785844 T ES08785844 T ES 08785844T ES 08785844 T ES08785844 T ES 08785844T ES 2389670 T8 ES2389670 T8 ES 2389670T8
- Authority
- ES
- Spain
- Prior art keywords
- pig
- treatment
- disorders associated
- synaptic transmission
- dysfunctional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0717388.3A GB0717388D0 (en) | 2007-09-07 | 2007-09-07 | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission |
GB0717388 | 2007-09-07 | ||
PCT/EP2008/007337 WO2009030498A2 (en) | 2007-09-07 | 2008-09-08 | Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2389670T3 ES2389670T3 (es) | 2012-10-30 |
ES2389670T8 true ES2389670T8 (es) | 2013-02-08 |
Family
ID=38640380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08785844T Active ES2389670T3 (es) | 2007-09-07 | 2008-09-08 | Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica desfuncional |
Country Status (7)
Country | Link |
---|---|
US (1) | US9062125B2 (es) |
EP (1) | EP2197475B1 (es) |
JP (1) | JP5670190B2 (es) |
CA (1) | CA2698766C (es) |
ES (1) | ES2389670T3 (es) |
GB (1) | GB0717388D0 (es) |
WO (1) | WO2009030498A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
UY33025A (es) | 2009-11-13 | 2011-06-30 | Sanofi Aventis Deustschland Gmbh | Composicion farmaceutica que comprende un agonista de glp-1 metionina |
AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
MX339614B (es) | 2010-08-30 | 2016-06-02 | Sanofi - Aventis Deutschland GmbH | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
GB201603510D0 (en) * | 2016-02-29 | 2016-04-13 | Univ Ulster | Compositions for use in the treatment of neurological disease |
JP7165496B2 (ja) * | 2016-12-26 | 2022-11-04 | 花王株式会社 | 認知機能改善剤 |
US11319369B2 (en) * | 2016-12-26 | 2022-05-03 | Kao Corporation | Motor control function improving agent |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0404124D0 (en) * | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
US7576050B2 (en) * | 2001-07-31 | 2009-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
AU2005215136A1 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | DPP-IV inhibitors for treating neurodegeneration and cognitive disorders |
EP1937716A2 (en) * | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
-
2007
- 2007-09-07 GB GBGB0717388.3A patent/GB0717388D0/en not_active Ceased
-
2008
- 2008-09-08 US US12/676,991 patent/US9062125B2/en active Active
- 2008-09-08 CA CA2698766A patent/CA2698766C/en active Active
- 2008-09-08 EP EP08785844A patent/EP2197475B1/en not_active Not-in-force
- 2008-09-08 JP JP2010523334A patent/JP5670190B2/ja not_active Expired - Fee Related
- 2008-09-08 ES ES08785844T patent/ES2389670T3/es active Active
- 2008-09-08 WO PCT/EP2008/007337 patent/WO2009030498A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US9062125B2 (en) | 2015-06-23 |
WO2009030498A3 (en) | 2009-04-23 |
EP2197475A2 (en) | 2010-06-23 |
ES2389670T3 (es) | 2012-10-30 |
GB0717388D0 (en) | 2007-10-17 |
CA2698766C (en) | 2018-07-31 |
CA2698766A1 (en) | 2009-03-12 |
EP2197475B1 (en) | 2012-08-01 |
US20100204106A1 (en) | 2010-08-12 |
JP5670190B2 (ja) | 2015-02-18 |
JP2010538030A (ja) | 2010-12-09 |
WO2009030498A2 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2389670T8 (es) | Uso del PIG para el tratamiento de trastornos asociados a la transmisión sináptica disfuncional | |
GB0717399D0 (en) | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission | |
BRPI0816209A2 (pt) | Artigos absorventes descartáveis do tipo para vestir com subsistemas de ancoramento. | |
CR11019A (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
BRPI0814405A2 (pt) | Aparelho para manutenção de poço com múltiplas finalidades | |
BRPI0807987A2 (pt) | Terapia de combinação para tratamento de distúrbios imunes. | |
BR112012013260A2 (pt) | dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa | |
BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
BRPI1008955A2 (pt) | Terapia de combinação com derivados de tiocolchicina. | |
ES2981249T3 (es) | Un dispositivo para el tratamiento de la obesidad | |
ATE537233T1 (de) | Beschichtete schleifprodukte mit aggregaten | |
BR112012011730A2 (pt) | tratamentos para distúrbios gastrointestinais | |
BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
ES2606627T8 (es) | Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis | |
BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
CL2008000110A1 (es) | Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos. | |
BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
BRPI0910496A2 (pt) | aplicação de rifalazil para tratar distúrbios colônicos. | |
BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
BRPI0810091A2 (pt) | Agentes fugicidas tópicos para tratar distúrbios ungueais | |
ES1065640Y (es) | Aparato para el alargamiento del pene | |
BRPI0813832A2 (pt) | Métodos para tratamento da ansiedade | |
BR112012002267A2 (pt) | compostos para o tratamento de inflamação. | |
BRPI0909659A2 (pt) | tratamento para distúrbios relacionados oculares |